Highest-materiality recent filing
Balchem shareholders elect directors, ratify auditor, approve say-on-pay at 2026 annual meeting
David Fischer and Daniel Knutson elected as Class 3 directors with 25.3M and 26.8M votes for, respectively.
Balchem Q1 net sales $270.7M (+8.1%); adjusted EBITDA $74.3M (+12.1%)
Net sales $270.7M, up 8.1% YoY; GAAP EPS $1.25, adjusted EPS $1.33.
Q4 net sales $263.6M (+9.8% YoY); GAAP EPS $1.21 vs $1.03; adjusted EPS $1.31 vs $1.13.
Balchem appoints Erin L. Gilson as CAO effective April 1, 2026
William A. Backus, VP and Chief Accounting Officer, retiring on March 31, 2026.
Balchem declares $0.96 annual dividend (10.3% increase), authorizes repurchase of up to 4M shares
Dividend of $0.96 per share declared on Dec 9, 2025, payable Jan 20, 2026 to holders of record Dec 23, 2025.
Balchem Q3 2025: record sales $267.6M, adj. EPS $1.35, all segments grow
Record net sales $267.6M (+11.5% YoY); GAAP EPS $1.24 vs $1.03; adjusted EPS $1.35 vs $1.13.
Balchem Q2 2025: record net sales $255.5M, adj. EPS $1.27 beat
Net sales $255.5M, +9.1% YoY; GAAP EPS $1.17 vs $0.98 prior year quarter.
Balchem shareholders elect three Class 1 directors, ratify auditor, approve say-on-pay
Theodore L. Harris elected with 24.96M votes for; 1.26M against; 963k abstain; 2.20M broker non-votes.
Balchem Q1 net sales $250.5M record; adj. EPS $1.22 vs $1.03 YoY; all segments grow
Net sales of $250.5M, up 4.5% YoY; GAAP EPS $1.13 vs $0.89; adjusted EPS $1.22 vs $1.03.
Balchem CAO William A. Backus to retire on March 31, 2026; successor not yet named
William A. Backus, Vice President and Chief Accounting Officer, notified of retirement effective March 31, 2026.
Balchem Q4 record net sales $240M, adjusted EBITDA $62.8M, EPS $1.03
Q4 net sales record $240.0M (+4.9% YoY); GAAP EPS $1.03 vs $0.82; adjusted EPS $1.13 vs $0.95.
Balchem adopts executive severance policy and enhances deferred comp match for officers
New Executive Severance Policy provides cash severance (multiple of salary plus target bonus) and COBRA for termination without Cause or Involuntary Termination within Change in Control (CIC) Period.
Balchem declares $0.87 dividend, 10.1% increase; payable Jan 17, 2025
Quarterly dividend set at $0.87 per share, a 10.1% increase versus prior year.
Balchem Q3 net sales up 4.3% to $239.9M; record adjusted EBITDA $64.4M, up 7.6% YoY
GAAP EPS $1.03 versus $0.90 prior year; adjusted EPS record $1.13 versus $1.04.
Joyce Lee resigns from Balchem board following planned employment change
Joyce Lee resigned as director on Oct 16, 2024, due to planned change in principal employment.
Directors Knutson, Lee, Vicente, and Fish moved among Class 1, 2, and 3 to approximate one-third per class, effective Sept 20, 2024.
Balchem Q2 net sales $234.1M (+1.2% YoY); record adjusted EBITDA $62.3M (+5.0%)
GAAP EPS $0.98 vs $0.93; adjusted EPS $1.09 vs $1.06.
Balchem shareholders elect four Class 2 directors and ratify RSM US LLP as auditor
Daniel Knutson, Joyce Lee, Olivier Rigaud, Monica Vicente elected as Class 2 directors (2027 term).
Balchem reports record Q1 net sales of $239.7M, adjusted EBITDA up 8%
Net sales $239.7M (+3.1% YoY), adjusted EBITDA $60.9M (+8.0% YoY), both all-time records.
Jonathan H. Griffin moves from SVP & GM, Animal Nutrition & Health to SVP, Corporate Development, effective immediately.
Balchem Q4 adj. EBITDA up 5.4% to $55.4M; free cash flow $56M, record Human Nutrition sales
Q4 GAAP EPS $0.82 vs $0.66 prior year; adjusted EPS $0.95 vs $0.94.
Balchem raises annual dividend 11.3% to $0.79/share
Board declared $0.79 per share dividend, an 11.3% increase over prior year.
Balchem Q3 sales down 5.9% to $229.9M, but EPS up to $0.90; record adjusted EBITDA $59.9M
GAAP EPS $0.90 vs $0.78 prior year; adjusted EPS $1.04 vs $1.00.
Balchem elects Olivier Rigaud and Monica Vicente to Board effective Sept 6, 2023
Olivier Rigaud, CEO of Corbion N.V., and Monica Vicente, CFO of Fresh Del Monte Produce Inc., join Balchem's Board as Class 2 directors.
Balchem Q2 sales $231.3M (-2.3% YoY); adjusted EPS $1.06; record EBITDA
Q2 net sales $231.3M, down 2.3% YoY; GAAP net earnings $30.1M ($0.93 EPS).
Balchem shareholders approve Amended 2017 Omnibus Incentive Plan, adding 800,000 authorized shares
Annual Meeting held June 22, 2023; Plan approved with 26,513,603 votes for (96.1% of votes cast).
Balchem reports record Q1 sales of $232.5M; net earnings down 21.5% to $22.7M
Record Q1 net sales of $232.5M (+1.6% YoY); gross margin $73.2M.
Balchem Q4 net sales up 9.1% to $232.5M; adjusted EPS $0.94; dividend raised 10.9%
Q4 net sales $232.5M (+9.1% YoY); GAAP net earnings $21.4M (-14.2%); adjusted net earnings $30.3M (+9.1%).
Board amended and restated Bylaws effective December 5, 2022.
Balchem declares Q4 dividend $0.71/share, 10.9% increase; 14th consecutive annual raise
Dividend of $0.71 per share payable Jan 20, 2023 to holders of record Dec 27, 2022.
Balchem Q3 revenue up 23.4% to $244.3M; adjusted EPS $1.00 vs $0.92 YoY
Net sales $244.3M (+23.4% YoY); GAAP EPS $0.78, adjusted EPS $1.00.
Balchem SVP & GM James Hyde to retire upon successor appointment; transition through 2023
James C. Hyde, SVP and General Manager of Human Nutrition & Health, notified company of retirement.
Balchem grants CEO Harris 130,000 options; $6.3M value for retention
130,000 stock options awarded to CEO Ted Harris with grant date Sep 15, 2022; fair value ~$6.3M.
Balchem files Kappa bioscience financials: 2021 revenue NOK 241M, net profit NOK 14.6M
Kappa (Kechu Bidco) 2021: revenue NOK 240.9M, op. profit NOK 42.7M, net profit NOK 14.6M including NOK 26.7M discontinued ops loss.
Balchem acquires Bergstrom Nutrition, maker of OptiMSM, for undisclosed sum
Albion Laboratories, a Balchem subsidiary, acquired Cardinal Associates (Bergstrom Nutrition), a global leader in MSM manufacturing.
Balchem enters $550M revolving credit facility, refinances existing debt
New $550M senior revolving credit facility matures in 5 years from July 27, 2022.
Balchem Q2 record net sales $236.7M (+17% YoY), GAAP EPS $0.92, adj. EPS $1.07
Record net sales $236.7M, up 17% YoY; GAAP EPS $0.92, adjusted EPS $1.07 (record).
Balchem closes $332.5M acquisition of Kappa Bioscience, financed via credit facility and cash
Purchase price ~NOK 3.3B ($332.5M) includes assumption and repayment of NOK 303.5M ($30.6M) of Kappa debt.
Balchem to acquire Kappa Bioscience for $338M; accretive to EPS in 2022
Enterprise value of NOK 3.175B (~$338M); EV/EBITDA multiple of 18x on 2022 forecast.
Balchem General Counsel and Secretary Mark Stach to retire by Dec 31, 2022
Mark Stach notified Balchem of his intent to retire; will step down upon appointment of a successor.
Net sales $228.9M (+23.3% YoY); GAAP net earnings $28.9M (+23.6% YoY); diluted GAAP EPS $0.89.
Balchem Q4 record sales $213M (+17.9% YoY); adj. EPS $0.85; dividend up 10.3%
Q4 net sales $213.1M (+17.9% YoY); GAAP EPS $0.76, adjusted EPS $0.85 (up from $0.83).
Balchem declares $0.64/share dividend, a 10.3% annual increase
Dividend of $0.64 per share, payable Jan 21, 2022, to holders of record Dec 28, 2021.
Balchem reports record Q3 2021 sales of $197.9M, net earnings $25.0M, EPS $0.77
Net sales $197.9M, up 13% YoY; record sales in all three segments: Human Nutrition, Animal Nutrition, and Specialty Products.
Balchem reports record Q2 sales of $202.4M, GAAP EPS $0.70, adjusted EPS $0.93, up 16.7% YoY
Record Q2 net sales $202.4M, up 16.7% YoY; all three segments set records.
William A. Backus, Vice President and Chief Accounting Officer, has notified the Company of his intent to retire from his position on March 31, 2026.
On October 16, 2024, the Corporate Governance and Nominating Committee of the Balchem Corporation (“Balchem”) Board of Directors (the “Board”) accepted the resignation of Joyce Lee as a Director.
On March 27, 2024, Balchem Corporation (the “Company”) announced that Jonathan H. Griffin, Senior Vice President and General Manager, Animal Nutrition and Health, would be moving into the role of Senior Vice President, Corporate Development, effective immediately.
On September 1, 2023, the Board of Directors (the “Board”) of Balchem Corporation (the “Company”) elected Olivier Rigaud and Monica Vicente to the Board, effective as of September 6, 2023, respectively.
On September 1, 2023, the Board of Directors (the “Board”) of Balchem Corporation (the “Company”) elected Olivier Rigaud and Monica Vicente to the Board, effective as of September 6, 2023, respectively.
James C. Hyde, Senior Vice President and General Manager, Human Nutrition & Health, has notified the Company of his intent to retire from his role and that he will step down upon the appointment of his successor.
On June 7, 2022, Balchem Corporation (the “ Company ”) announced that Mark Stach, General Counsel and Secretary of the Company, has notified the Company of his intent to retire and will step down upon the appointment of his successor.
Max materiality 0.80 · Median 0.60 · Most common event earnings